Microbiotica announces the appointment of Dr Robert Tansley as Chief Medical Officer
Cambridge, UK – 10 June 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that Dr Robert Tansley is appointed Chief Medical Officer with immediate effect.
Dr Tansley steps into the role at a key development stage for Microbiotica with its two lead programmes progressing through Phase 1 clinical trials in immuno-oncology (MB097 for advanced melanoma), and inflammatory bowel disease (MB310 for ulcerative colitis) with data read-outs anticipated this year.
Dr Robert Tansley commented: “I am delighted to be expanding my role at Microbiotica at this exciting time for the Company as it completes early clinical efficacy studies. Having initially joined the Board of Directors when Cambridge Innovation Capital (CIC) co-led the seed investment round in 2016, it has been a pleasure to work with such an outstanding group of academics, scientists and drug developers and to see the Company approach these key inflection points.”
“The rapidly expanding academic literature supports the huge potential of the microbiome for positively impacting human disease. Many of the challenges experienced in demonstrating the clinical utility of LBPs in recent years may have been down to underestimating the complexity of the microbiome. Having studied the field for the last decade, I believe that Microbiotica has the most robust scientific approach for the discovery and development of defined LBPs, based on a foundation of clinical data and a keen focus on understanding disease mechanism. This gives Microbiotica the chance of making a real breakthrough in this new modality through the development of safe, clinically differentiated therapies”.
“This is the right time for me to pursue a long-standing scientific and clinical interest in the microbiome field by taking on an executive role, while continuing to oversee my responsibilities at CIC. I’m looking forward to contributing more deeply to Microbiotica’s mission and its exciting future.”
Dr Tansley will join the Company on a part-time basis as he continues his responsibilities with CIC. He will step down as a Microbiotica Board Director as he takes up this role and, in his place, Dr Anne Horgan will be appointed to the Microbiotica Board as CIC’s Investor Director.
Dr Ron Carter, who has served as consultant Chief Medical Officer will stay with the Company as Senior Vice-President, Medical Affairs and will continue to oversee the medical management of its ongoing studies.
Tim Sharpington, Microbiotica CEO, said: “We are excited that Robert is joining at this key time in the Company’s evolution. His experience as a drug developer and investor will greatly strengthen our management team as we approach key data read-outs in our first clinical trials and make plans for future growth.”
“I look forward to working closely with Robert as a key member of our executive team and with Anne Horgan as our new director. She brings over 20 years’ experience, spanning across all aspects of Life Sciences innovation from drug discovery, technology transfer and business development to equity financing that will be valuable as we grow.”
– ENDS –
Notes to Editors
About Dr Robert Tansley
After an early career in hospital medicine, Robert built up over 25 years’ experience in the biopharmaceutical industry. He gained development and regulatory skills through roles of increasing responsibility at Sanofi, MHRA and Roche before spending a decade at early-stage biotech companies, including Medical Director at Arakis (sold to Sosei Inc), founder and CEO at Treague, founding CEO of the University of Copenhagen spin-out Avilex Pharma and founding Chief Medical Officer of KalVista (Nasdaq: KALV). In 2014, Robert joined Cambridge Innovation Capital (CIC) as a Partner managing CIC’s investments in Inivata (sold to NeoGenomics), Gyroscope Therapeutics (sold to Novartis), Z Factor, Morphogen-IX (each part of the roll-up with Centessa), Abcodia (sold to GenIncode) and PetMedix (sold to Zoetis). Robert will maintain his position at CIC where he will continue to oversee CIC’s investments in CMR Surgical, Sortera.bio, Pretzel Therapeutics and T-Therapeutics.
Robert qualified in medicine from UCL. He is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine (passed with distinction) and has an MBA (passed with distinction) from London Business School and an MPhil in Biostatistics from the University of Cambridge.
About Microbiotica
Microbiotica is a private, clinical-stage, biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs) with lead programmes in immuno-oncology and inflammatory bowel disease. The Company has a clinic-led, purpose-built, proprietary, microbiome profiling platform to support drug discovery based on clinical data, which enables precision identification of bacteria associated with favourable clinical trial outcomes in specific patient populations. The Company has significant expertise in microbiology, bioinformatics, translational biology and LBP manufacturing and development.
The Company is creating a novel pipeline of programmes in immuno-oncology (MB097 for advanced melanoma), and inflammatory bowel disease (MB310 for ulcerative colitis). It has a major partnership with Cancer Research UK and Cambridge University Hospitals in immuno-oncology. The Company has a clinical trial supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) for use of KEYTRUDA in evaluating MB097 in melanoma patients with primary resistance to anti-PD-1 immunotherapy. MB310 was developed in collaboration with the University of Adelaide. Both programmes have data read-outs in 2025.
Spun out of the Wellcome Sanger Institute in 2016, the Company is based in purpose-built facilities at the Chesterford Research Park near Cambridge, UK. Microbiotica has raised more than £62 million equity investment, including a £50 million Series B in 2022, with venture investors including British Patient Capital, Cambridge Innovation Capital, Flerie Invest, IP Group plc, Seventure Partners and Tencent. The Company has also received financial support from the US-based Crohn’s and Colitis Foundation.
For more information, please visit www.microbiotica.com, and follow us on LinkedIn.
Media contacts
Microbiotica
Ro Gardner, rgardner@microbiotica.com, +44 7801 480569
Scius Communications
Sue Charles, sue@sciuscommunications.com, +44 7968 726585
Katja Stout, katja@sciuscommunications.com, +44 7789 435990
Daniel Gooch, daniel@sciuscommunications.com, +44 7747 875479
